We work to improve the quality of life of patients with spinal cord injuries, strokes, and other diseases affecting the central nervous system.
Drug repurposing to improve the lives of patients with CNS disorders.
About Sinfatin
In Sinfatin SL We investigate new indications for marketed drugs. We are looking for solutions for patients with diseases of the nervous system through drug repositioning, which allows us to reduce development times and offer safe and effective solutions to patients.
We have an expert team composed of physicians, biologists, pharmacists, and professionals with solid training and extensive clinical and scientific experience. Our team is committed to a common goal: improve the quality of life of people living with spinal cord injury, stroke and other central nervous system (CNS) diseases.
Therapeutic areas
At Sinfatin we work to offer real solutions to patients with diseases of the central nervous systemOur commitment is based on the research and development of treatments through the repositioning of drugs.
Spinal cord injury
Ictus
Other pathologies
Rimonabant
We have an ongoing clinical development program with rimonabant aimed at treating fatigue, both physical and mental, and improving ambulation, performance and quality of life in patients with Central Nervous System (CNS) diseases, such as spinal cord injury or stroke, and in patients with persistent COVID-19.
Rimonabant is an antagonist/inverse agonist of endocannabinoid receptors located predominantly in the CNS. This drug has a well-established safety profile and is being evaluated in clinical trials for its repositioning as a possible treatment for fatigue and related functional symptoms caused by various CNS disorders.
Chemical structure of SR141716A (Rimonabant)
To the project “Research and development of liquid oral formulations of rimonabant for applications in the central nervous system”The project with file number ZL-2026/00803 (RIMONABE), led by Sinfatin SL, has been granted aid from the Business R&D Support Program – HAZITEK of the Basque Government.
This action is co-financed by the Basque Government and the European Union through the European Regional Development Fund 2021-2027 (ERDF).
Sinfatin has been granted the help with contracts Torres Quevedo (PTQ) 2025 within the State Plan for Scientific and Technical Research and Innovation 2024-2027.
The hiring linked to the project “Clinical and translational research of rimonabant as a motor function stimulator in spinal cord injury” It is part of the PTQ2025-014380 aid, funded by the MICIU/AEI/10.13039/501100011033.»
Contact form
Are you interested in learning more about Sinfatin and our developments?
We are here to help you. Write to us and we will respond as soon as possible.
We work to improve the lives of those living with central nervous system disorders by mitigating fatigue due to damage to motor systems.
Our commitment is to move toward more effective, safe, and accessible treatments.